Mechanisms of absorption and elimination of drugs administered by inhalation

Therapeutic Delivery

Volumn 4, Issue 8, 2013, Pages 1027-1045

  Ibrahim, Mariam ^a   Garcia Contreras, Lucila ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; LUNG SURFACTANT; MULTIDRUG RESISTANCE PROTEIN 1;

AEROSOL; CYTOPLASM; DIFFUSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG TARGETING; DRUG TRANSPORT; ENZYMATIC DEGRADATION; HUMAN; IN VITRO STUDY; LUNG; MACROPHAGE; MEMBRANE VESICLE; MUCOCILIARY CLEARANCE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; RESPIRATORY SYSTEM; REVIEW; TIGHT JUNCTION; TRANSCYTOSIS; UPPER RESPIRATORY TRACT; VASCULARIZATION;

EID: 84881487990     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.13.67     Document Type: Review

References (140)

1. Edwards DA, Ben-Jebria A, Langer R. Recent advances in pulmonary drug delivery using large, porous inhaled particles. J. Appl. Physiol. 85(2), 379-385 (1998).
2. Biron A. Current therapeutic methods in the thorough treatment of asthma. Concours. Med. 85, 7019-7026 (1963).
3. Noymer P, Biondi S, Myers D, Cassella J. Pulmonary delivery of therapeutic compounds for treating CNS disorders. Ther. Deliv. 2(9), 1125-1140 (2011).
4. Agu RU, Ugwoke MI, Armand M, Kinget R, Verbeke N. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir. Res. 2(4), 198-209 (2001).
5. Sanjar S, Matthews J. Treating systemic diseases via the lung. J. Aerosol Med. 14(Suppl. 1), S51-S58 (2001).
6. Ehrhardt C, Fiegel J, Fuchs S et al. Drug absorption by the respiratory mucosa: cell culture models and particulate drug carriers. J. Aerosol Med. 15(2), 131-139 (2002).
7. Mcelroy MC, Kirton C, Gliddon D, Wolff RK. Inhaled biopharmaceutical drug development: nonclinical considerations and case studies. Inhal. Toxicol. 25(4), 219-232 (2013).
8. Davis SN. The role of inhaled insulin in the treatment of type 2 diabetes. J. Diabetes Complications 22(6), 420-429 (2008).
9. Garcia-Contreras L, Morcol T, Bell S, Hickey AJ. Evaluation of novel calcium phosphate particles as pulmonary delivery systems for insulin in rats. AAPS PharmSci 3(3), E9 (2001).
10. Chono S, Fukuchi R, Seki T, Morimoto K. Aerosolized liposomes with dipalmitoyl phosphatidylcholine enhance pulmonary insulin delivery. J. Control. Release 137(2), 104-109 (2009).
11. Liu J, Gong T, Fu H et al. Solid lipid nanoparticles for pulmonary delivery of insulin. Int. J. Pharm. 356(1-2), 333-344 (2008).
12. Al-Qadi S, Grenha A, Carrion-Recio D, Seijo B, Remunan-Lopez C. Microencapsulated chitosan nanoparticles for pulmonary protein delivery: in vivo evaluation of insulin-loaded formulations. J. Control. Release 157(3), 383-390 (2012).
13. Forbes B, Asgharian B, Dailey LA et al. Challenges in inhaled product development and opportunities for open innovation. Adv. Drug Deliv. Rev. 63(1-2), 69-87 (2011).
14. Lipworth BJ. Pharmacokinetics of inhaled drugs. Br. J. Clin. Pharmacol. 42(6), 697-705 (1996).
15. Patton JS, Brain JD, Davies LA et al. The particle has landed - characterizing the fate of inhaled pharmaceuticals. J. Aerosol Med. Pulm. Drug Deliv. 23(Suppl. 2), S71-S87 (2010).
16. Bo Olsson EB, Borgström L, Edsbäcker S et al. Pulmonary drug metabolism, clearance, and absorption. In: Controlled Pulmonary Drug Delivery, 21, Advances in Delivery Science and Technology. Smith HDC, Hickey AJ (Eds). Springer (2011).
17. Sporty JL, Horalkova L, Ehrhardt C. In vitro cell culture models for the assessment of pulmonary drug disposition. Expert Opin. Drug Metab. Toxicol. 4(4), 333-345 (2008).
18. Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat. Rev. Drug Discov. 6(1), 67-74 (2007).
19. Patton JS. Mechanisms of macromolecules absorption in the lungs. Adv. Drug Deliv. Rev. 19, 34 (1996).
20. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol. 56(6), 588-599 (2003).
21. Forbes II. Human airway epithelial cell lines for in vitro drug transport and metabolism studies. Pharm. Sci. Technol. Today 3(1), 18-27 (2000).
22. Dahan A, Miller JM, Amidon GL. Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs. AAPS J. 11(4), 740-746 (2009).
23. Gumbleton M, Hollins AJ, Omidi Y, Campbell L, Taylor G. Targeting caveolae for vesicular drug transport. J. Control. Release 87(1-3), 139-151 (2003).
24. Florea BI, Cassara ML, Junginger HE, Borchard G. Drug transport and metabolism characteristics of the human airway epithelial cell line Calu-3. J. Control. Release 87, 131-138 (2003).
25. Kim K-J, Borok Z, Crandall ED. A useful in vitro model for transport studies of alveolar epithelial barrier. Pharm. Res. 18(3), 253-255 (2001).
26. Kim K-J, Malik AB. Protein transport across the lung epithelial barrier. Am. J. Physiol. 284(2 Pt. 1), L247-L259 (2003).
27. Weers JG, Bell J, Chan HK et al. Pulmonary formulations: what remains to be done? J. Aerosol Med. Pulm. Drug Deliv. 23(Suppl. 2), S5-S23 (2010).
28. Sakagami M. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv. Drug Deliv. Rev. 58(9-10), 1030-1060 (2006).
29. Steimer A, Haltner E, Lehr CM. Cell culture models of the respiratory tract relevant to pulmonary drug delivery. J. Aerosol Med. 18(2), 137-182 (2005).
30. Forbes B, Ehrhardt C. Human respiratory epithelial cell culture for drug delivery applications. Eur. J. Pharm. Biopharm. 60(2), 193-205 (2005).
31. Tronde A, Norden B, Jeppsson AB et al. Drug absorption from the isolated perfused rat lung - correlations with drug physicochemical properties and epithelial permeability. J. Drug Target. 11(1), 61-74 (2003).
32. Florea BI, Cassara ML, Junginger HE, Borchard G. Drug transport and metabolism characteristics of the human airway epithelial cell line Calu-3. J. Control. Release 87(1-3), 131-138 (2003).
33. Salomon JJ, Ehrhardt C. Organic cation transporters in the blood-air barrier: expression and implications for pulmonary drug delivery. Ther. Deliv. 3(6), 735-747 (2012).
34. Ehrhardt C, Kneuer C, Laue M, Schaefer UF, Kim K-J, Lehr C-M. 16HBE14o-human bronchial epithelial cell layers express P-glycoprotein, lung resistance-related protein, and caveolaen-1. Pharm. Res. 20(4), 545-551 (2003).
35. Puri N, Prakash O, Manoharlal R, Sharma M, Ghosh I, Prasad R. Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans. Eur. J. Med. Chem. 45(11), 4813-4826 (2010).
36. Bur M, Huwer H, Lehr CM et al. Assessment of transport rates of proteins and peptides across primary human alveolar epithelial cell monolayers. Eur. J. Pharm. Sci. 28(3), 196-203 (2006).
37. Rothen-Rutishauser BM, Kiama SG, Gehr P. A three-dimensional cellular model of the human respiratory tract to study the interaction with particles. Am. J. Respir. Cell Mol. Biol. 32(4), 281-289 (2005).
38. Cheek JM, Kim K-J, Crandall ED. Tight monolayers of rat alveolar epithelial cells: bioelectric properties and active sodium transport. Am. J. Physiol. 256(25), C688-C693 (1989).
39. Matsukawa Y, Yamahara H, Yamashita F, Lee VHL, Crandall ED, Kim K-J. Rates of protein transport across rat alveolar epithelial cell monolayers. J. Drug Target. 7, 335-342 (2000).
40. Frank JA. Claudins and alveolar epithelial barrier function in the lung. Ann. NY Acad. Sci. 1257, 175-183 (2012).
41. Koval M. Tight junctions, but not too tight: fine control of lung permeability by claudins. Am. J. Physiol. Lung Cell Mol. Physiol. 297(2), L217-L218 (2009).
42. Schneeberger EE, Lynch RD. The tight junction: a multifunctional complex. Am. J. Physiol. Cell Physiol. 286(6), C1213-C1228 (2004).
43. Frank PG, Woodman SE, Park DS, Lisanti MP. Caveolaen, caveolae, and endothelial cell function. Arterioscler. Thromb. Vasc. Biol. 23(7), 1161-1168 (2003).
44. Stewart CE, Torr EE, Mohd Jamili NH, Bosquillon C, Sayers I. Evaluation of differentiated human bronchial epithelial cell culture systems for asthma research. J. Allergy (Cairo) Article ID 943982 (2012) (2012).
45. Konsoula R, Barile FA. Correlation of in vitro cytotoxicity with paracellular permeability in Caco-2 cells. Toxicol. In Vitro 19(5), 675-684 (2005).
46. Vllasaliu D, Casettari L, Fowler R et al. Absorption-promoting effects of chitosan in airway and intestinal cell lines: a comparative study. Int. J. Pharm. 430(1-2), 151-160 (2012).
47. Murata M, Tamai I, Sai Y, Nagata O, Kato H, Tsuji A. Carrier-mediated lung distribution of HSR-903, a new quinolone antibacterial agent. J. Pharmacol. Exp. Ther. 289(1), 79-84 (1999).
48. Bosquillon C. Drug transporters in the lung - do they play a role in the biopharmaceutics of inhaled drugs? J. Pharm. Sci. 99(5), 2240-2255 (2010).
49. Gumbleton M, Al-Jayyoussi G, Crandon-Lewis A et al. Spatial expression and functionality of drug transporters in the intact lung: objectives for further research. Adv. Drug Deliv. Rev. 63(1-2), 110-118 (2011).
50. Horvath G, Schmid N, Fragoso MA et al. Epithelial organic cation transporters ensure pH-dependent drug absorption in the airway. Am. J. Respir. Cell Mol. Biol. 36(1), 53-60 (2007).
51. Nakanishi T, Hasegawa Y, Haruta T, Wakayama T, Tamai I. In vivo evidence of organic cation transporter-mediated tracheal accumulation of the anticholinergic agent ipratropium in mice. J. Pharm. Sci. doi:10.1002/jps.23603 (2013) (Epub ahead of print).
52. Roth M, Obaidat A, Hagenbuch B. OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br. J. Pharmacol. 165(5), 1260-1287 (2012).
53. Groneberg DA, Nickolaus M, Springer J, Doring F, Daniel H, Fischer A. Localization of the peptide transporter PEPT2 in the lung: implications for pulmonary oligopeptide uptake. Am. J. Pathol. 158(2), 707-714 (2001).
54. Groneberg DA, Eynott PR, Doring F et al. Distribution and function of the peptide transporter PEPT2 in normal and cystic fibrosis human lung. Thorax 57(1), 55-60 (2002).
55. Hamilton KO, Yazdanian MA, Audus KL. Modulation of P-glycoprotein activity in Calu-3 cells using steroids and beta-ligands. Int. J. Pharm. 228(1-2), 171-179 (2001).
56. Bandi N, Kompella UB. Budesonide reduces multidrug resistance-associated protein 1 expression in an airway epithelial cell line (Calu-1). Eur. J. Pharmacol. 437(1-2), 9-17 (2002).
57. Al-Jayyoussi G, Price DF, Francombe D et al. Selectivity in the impact of P-glycoprotein upon pulmonary absorption of airway-dosed substrates: a study in ex vivo lung models using chemical inhibition and genetic knockout. J. Pharm. Sci. doi:10.1002/jps.23587 (2013) (Epub ahead of print).
58. Van Der Deen M, De Vries EG, Timens W, Scheper RJ, Timmer-Bosscha H, Postma DS. ATP-binding cassette (ABC) transporters in normal and pathological lung. Respir. Res. 6, 59 (2005).
59. Lehmann T, Kohler C, Weidauer E, Taege C, Foth H. Expression of MRP1 and related transporters in human lung cells in culture. Toxicology 167(1), 59-72 (2001).
60. Endter S, Becker U, Daum N et al. P-glycoprotein (MDR1) functional activity in human alveolar epithelial cell monolayers. Cell Tissue Res. 328(1), 77-84 (2007).
61. Gumbleton M. Caveolae as potential macromolecule trafficking compartments within alveolar epithelium. Adv. Drug Deliv. Rev. 49(3), 281-300 (2001).
62. Drab M, Verkade P, Elger M et al. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolaen-1 gene-disrupted mice. Science 293(5539), 2449-2452 (2001).
63. Parkar NS, Akpa BS, Nitsche LC et al. Vesicle formation and endocytosis: function, machinery, mechanisms, and modeling. Antioxid. Redox Signal. 11(6), 1301-1312 (2009).
64. Herd H, Daum N, Jones AT, Huwer H, Ghandehari H, Lehr CM. Nanoparticle geometry and surface orientation influence mode of cellular uptake. ACS Nano 7(3), 1961-1973 (2013).
65. Mall MA. Role of cilia, mucus, and airway surface liquid in mucociliary dysfunction: lessons from mouse models. J. Aerosol Med. Pulm. Drug Deliv. 21(1), 13-24 (2008).
66. Stannard W, O'Callaghan C. Ciliary function and the role of cilia in clearance. J. Aerosol Med. 19(1), 110-115 (2006).
67. Antunes MB, Cohen NA. Mucociliary clearance - a critical upper airway host defense mechanism and methods of assessment. Curr. Opin. Allergy Clin. Immunol. 7(1), 5-10 (2007).
68. Widdicombe JG. Airway liquid: a barrier to drug diffusion? Eur. Respir. J. 10(10), 2194-2197 (1997).
69. Schuster BS, Suk JS, Woodworth GF, Hanes J. Nanoparticle diffusion in respiratory mucus from humans without lung disease. Biomaterials 34(13), 3439-3446 (2013).
70. Akella A, Deshpande SB. Pulmonary surfactants and their role in pathophysiology of lung disorders. Indian J. Exp. Biol. 51(1), 5-22 (2013).
71. Thum T, Erpenbeck VJ, Moeller J, Hohlfeld JM, Krug N, Borlak J. Expression of xenobiotic metabolizing enzymes in different lung compartments of smokers and nonsmokers. Environ. Health Perspect. 114(11), 1655-1661 (2006).
72. Foster KA, Avery ML, Yazdanian M, Audus KL. Characterization of the Calu-3 cell line as a tool to screen pulmonary drug delivery. Int. J. Pharm. 208(1-2), 1-11 (2000).
73. Foster KA, Oster CG, Mayer MM, Avery ML, Audus KL. Characterization of the A549 cell line as a type II pulmonary epithelial cell model for drug metabolism. Exp. Cell Res. 243(2), 359-366 (1998).
74. Somers GI, Lindsay N, Lowdon BM et al. A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes. Drug Metab. Dispos. 35(10), 1797-1805 (2007).
75. Leclerc J, Courcot-Ngoubo Ngangue E, Cauffiez C et al. Xenobiotic metabolism and disposition in human lung: transcript profiling in non-tumoral and tumoral tissues. Biochimie 93(6), 1012-1027 (2011).
76. Rubins JB. Alveolar macrophages: wielding the double-edged sword of inflammation. Am. J. Respir. Crit. Care Med. 167(2), 103-104 (2003).
77. Jakab GJ, Risby TH, Sehnert SS, Hmieleski RR, Farrington JE. Suppression of alveolar macrophage membrane receptor-mediated phagocytosis by model and actual particle-adsorbate complexes. Initial contact with the alveolar macrophage membrane. Environ. Health Perspect. 86, 337-344 (1990).
78. Edwards DA, Hanes J, Caponetti G et al. Large porous particles for pulmonary drug delivery. Science 276(5320), 1868-1871 (1997).
79. Chakravarthy KV, Davidson BA, Helinski JD et al. Doxorubicin-conjugated quantum dots to target alveolar macrophages and inflammation. Nanomedicine 7(1), 88-96 (2011).
80. Oberdorster G, Ferin J, Gelein R, Soderholm SC, Finkelstein J. Role of the alveolar macrophage in lung injury: studies with ultrafine particles. Environ. Health Perspect. 97, 193-199 (1992).
81. Pang KS. Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series). Drug Metab. Dispos. 31(12), 1507-1519 (2003).
82. Eixarch H, Haltner-Ukomadu E, Beisswenger C, Bock U. Drug delivery to the lung: permeability and physicochemical characteristics of drugs as the basis for a pulmonary biopharmaceutical classification system (pBCS). J. Epithel. Biol. Pharmacol. 3, 15 (2010).
83. Schanker L, Mitchel E, Brown R. Species comparison of drug absorption from the lung after inhalation or intratracheal injection. Drug Metab. Dispos. 14, 79-88 (1986).
84. Patton JS, Fishburn CS, Weers JG. The lungs as a portal of entry for systemic drug delivery. Proc. Am. Thorac. Soc. 1(4), 338-344 (2004).
85. Tronde A, Norden B, Marchner H, Wendel AK, Lennernas H, Bengtsson UH. Pulmonary absorption rate and bioavailability of drugs in vivo in rats: structure-absorption relationships and physicochemical profiling of inhaled drugs. J. Pharm. Sci. 92(6), 1216-1233 (2003).
86. Hussain A, Arnold JJ, Khan MA, Ahsan F. Absorption enhancers in pulmonary protein delivery. J. Control. Release 94(1), 15-24 (2004).
87. Haslam IS, Jones K, Coleman T, Simmons NL. Rifampin and digoxin induction of MDR1 expression and function in human intestinal (T84) epithelial cells. Br. J. Pharmacol. 154(1), 246-255 (2008).
88. Garcia-Contreras L, Hickey AJ. Pharmaceutical and biotechnological aerosols for cystic fibrosis therapy. Adv. Drug Deliv. Rev. 54(11), 1491-1504 (2002).
89. Ohta H, Chiba S, Ebina M, Furuse M, Nukiwa T. Altered expression of tight junction molecules in alveolar septa in lung injury and fibrosis. Am. J. Physiol. Lung Cell Mol. Physiol. 302(2), L193-L205 (2012).
90. Nicolazzo JA. Transporters in the pathogenesis of alzheimer's disease. Presented at: AAPS Workshop on Drug Transporters in ADME: From the Bench to the Bedside. Bethesda, MD, USA, 17-20 March (2013).
91. Fountaine R, Milton A, Checchio T et al. Acute passive cigarette smoke exposure and inhaled human insulin (Exubera) pharmacokinetics. Br. J. Clin. Pharmacol. 65(6), 864-870 (2008).
92. Lickteig AJ, Fisher CD, Augustine LM et al. Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease. Drug Metab. Dispos. 35(10), 1970-1978 (2007).
93. Mizuno N, Niwa T, Yotsumoto Y, Sugiyama Y. Impact of drug transporter studies on drug discovery and development. Pharmacol. Rev. 55(3), 425-461 (2003).
94. Kim I, Byeon HJ, Kim TH et al. Doxorubicin-loaded highly porous large PLGA microparticles as a sustained-release inhalation system for the treatment of metastatic lung cancer. Biomaterials 33(22), 5574-5583 (2012).
95. Latimer P, Menchaca M, Snyder RM et al. Aerosol delivery of liposomal formulated paclitaxel and vitamin E analog reduces murine mammary tumor burden and metastases. Exp. Biol. Med. (Maywood) 234(10), 1244-1252 (2009).
96. Selting K, Waldrep JC, Reinero C et al. Feasibility and safety of targeted cisplatin delivery to a select lung lobe in dogs via the AeroProbe intracorporeal nebulization catheter. J. Aerosol Med. Pulm. Drug Deliv. 21(3), 255-268 (2008).
97. Bauldoff GS, Nunley DR, Manzetti JD, Dauber JH, Keenan RJ. Use of aerosolized colistin sodium in cystic fibrosis patients awaiting lung transplantation. Transplantation 64(5), 748-752 (1997).
98. Claridge JA, Edwards NM, Swanson J et al. Aerosolized ceftazidime prophylaxis against ventilator-associated pneumonia in high-risk trauma patients: results of a double-blind randomized study. Surg. Infect. (Larchmt) 8(1), 83-90 (2007).
99. Falagas ME, Agrafiotis M, Athanassa Z, Siempos II. Administration of antibiotics via the respiratory tract as monotherapy for pneumonia. Expert Rev. Anti Infect. Ther. 6(4), 447-452 (2008).
100. Garcia-Contreras L, Fiegel J, Telko MJ et al. Inhaled capreomycin large porous particles for the treatment of tuberculosis in the guinea pig model. Antimicrob. Agents Chemother. 51(8), 2830-2836 (2007).
101. Garcia-Contreras L, Sethuraman V, Kazantseva M, Hickey AJ. Evaluation of dosing regimen of respirable rifampicin biodegradable microspheres doses in the treatment of tuberculosis in the guinea pig. J. Antimicrob. Chemother. 58(9), 980-986 (2006).
102. Goldstein I, Wallet F, Nicolas-Robin A, Ferrari F, Marquette CH, Rouby JJ. Lung deposition and efficiency of nebulized amikacin during Escherichia coli pneumonia in ventilated piglets. Am. J. Respir. Crit. Care Med. 166(10), 1375-1381 (2002).
103. Horianopoulou M, Lambropoulos S, Papafragas E, Falagas ME. Effect of aerosolized colistin on multidrug-resistant Pseudomonas aeruginosa in bronchial secretions of patients without cystic fibrosis. J. Chemother. 17(5), 536-538 (2005).
104. Muttil P, Kaur J, Kumar K, Yadav AB, Sharma R, Misra A. Inhalable microparticles containing large payload of anti-tuberculosis drugs. Eur. J. Pharm. Sci. 32(2), 140-150 (2007).
105. Palmer LB, Smaldone GC, Chen JJ et al. Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit. Crit. Care Med. 36(7), 2008-2013 (2008).
106. Pandey R, Sharma A, Zahoor A, Sharma S, Khuller GK, Prasad B. Poly (d,l-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J. Antimicrob. Chemother. 52(6), 981-986 (2003).
107. Safdar A, Shelburne SA, Evans SE, Dickey BF. Inhaled therapeutics for prevention and treatment of pneumonia. Expert Opin. Drug Saf. 8(4), 435-449 (2009).
108. Tsapis N, Bennett D, O'Driscoll K et al. Direct lung delivery of para-aminosalicylic acid by aerosol particles.Tuberculosis 83(6), 379-385 (2003).
109. Adi H, Young PM, Chan HK, Stewart P, Agus H, Traini D. Cospray dried antibiotics for dry powder lung delivery. J. Pharm. Sci. 97(8), 3356-3366 (2008).
110. Gappa M, Steinkamp G, Tummler B, Von Der Hardt H. Long-term tobramycin aerosol therapy of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis. Scand. J. Gastroenterol. 143, 74-76 (1988).
111. Gueders MM, Bertholet P, Perin F et al. A novel formulation of inhaled doxycycline reduces allergen-induced inflammation, hyperresponsiveness and remodeling by matrix metalloproteinases and cytokines modulation in a mouse model of asthma. Biochem. Pharmacol. 75(2), 514-526 (2008).
112. Hodson ME, Penket ARL, Baten JC. Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lancet 2, 1137-1139 (1981).
113. Jensen T, Pedersen SS, Garne S, Heilman C, Hoiby N, Koch C. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J. Antimicrob. Ther. 19, 831-838 (1987).
114. Stead RJ, Hodson ME, Baten JC. Inhaled ceftazidime compared with gentamicin and carbenicillin in older patients with cystic fibrosis infected with Pseudomonas aeruginosa. Br. J. Dis. Chest 81, 272-279 (1987).
115. Vaughan WC, Carvalho G. Use of nebulized antibiotics for acute infections in chronic sinusitis. Otolaryngol. Head Neck Surg. 127(6), 558-568 (2002).
116. America ATSIDSO. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 171(4), 388-416 (2005).
117. Michalopoulos A, Fotakis D, Virtzili S et al. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study. Respir. Med. 102(3), 407-412 (2008).
118. Standridge JB, Aliff CL. Aerosolized amikacin in the treatment of Pseudomonas pneumonia in the nursing home setting. South Med. J. 94(2), 244-246 (2001).
119. Mubareka S, Rubinstein E. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Crit. Care 9(1), 29-30 (2005).
120. Pereira GH, Muller PR, Levin AS. Salvage treatment of pneumonia and initial treatment of tracheobronchitis caused by multidrug-resistant Gram-negative bacilli with inhaled polymyxin B. Diagn. Microbiol. Infect. Dis. 58(2), 235-240 (2007).
121. Dhuley JN. Aerosol hamycin is effective for prophylaxis and therapy in a rat model of pulmonary aspergillosis. Rocz. Akad. Med. Bialymst. 46, 317-325 (2001).
122. Monforte V, Roman A, Gavaldá J et al. Nebulized amphotericin B concentration and distribution in the respiratory tract of lung-transplanted patients. Transplantation 75(9), 1571-1574 (2003).
123. Tolman JA, Wiederhold NP, McConville JT et al. Inhaled voriconazole for prevention of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 53(6), 2613-2615 (2009).
124. Niven RW. Toward managing chronic rejection after lung transplant: the fate and effects of inhaled cyclosporine in a complex environment. Adv. Drug Deliv. Rev. 63(1-2), 88-109 (2011).
125. Jonas DE, Wines RCM, Delmonte M et al. Drug class review: controller medications for asthma. Final Update 1 Report. Oregon Health and Science University, Portland, OR, USA (2011).
126. Hitzman CJ, Wattenberg LW, Wiedmann TS. Pharmacokinetics of 5-fluorouracil in the hamster following inhalation delivery of lipid-coated nanoparticles. J. Pharm. Sci. 95(6), 1196-1211 (2006).
127. Rodriguez CO, Crabbs TA, Wilson DW et al. Aerosol gemcitabine: preclinical safety and in vivo antitumor activity in osteosarcoma-bearing dogs. J. Aerosol Med. Pulm. Drug Deliv. 22(4), 1-10 (2009).
128. Cipolla DC, Gonda I, Shak S, Kovesdi I, Crystal R, Sweeney TD. Coarse spray delivery to a localized region of the pulmonary airways for gene therapy. Hum. Gene Ther. 11(2), 361-371 (2000).
129. Hubbard R, Crystal RG. Strategies for aerosol therapy of alpha 1-antitrypsin deficiency by the aerosol route. Lung 168, 564-578 (1990).
130. Hubbard R, Mcelvaney NG, Birrer P et al. A preliminary study of recombinant human desoxyribonuclease I in the treatment of cystic fibrosis. N Eng. J. Med. 326, 812-815 (1992).
131. Gibbons A, Padilla-Carlin D, Kelly C et al. The effect of liposome encapsulation on the pharmacokinetics of recombinant secretory leukocyte protease inhibitor (rSLPI) therapy after local delivery to a guinea pig asthma model. Pharm. Res. 28(9), 2233-2245 (2011).
132. Jansen M, Darby I, Abribat T, Dubreuil P, Ferdinandi ES, Hardy JG. Pulmonary delivery of TH9507, a growth hormone releasing factor analogue, in the dog. Int. J. Pharm. 276(1-2), 75-81 (2004).
133. Shoyele SA, Sivadas N, Cryan SA. The effects of excipients and particle engineering on the biophysical stability and aerosol performance of parathyroid hormone (1-34) prepared as a dry powder for inhalation. AAPS PharmSciTech 12(1), 304-311 (2011).
134. Zheng JY, Fulu MY, Lee DY, Barber TE, Adjei AL. Pulmonary peptide delivery: effect of taste-masking excipients on leuprolide suspension metered-dose inhalers. Pharm. Dev. Technol. 6(4), 521-530 (2001).
135. Rackley CR, Stripp BR. Building and maintaining the epithelium of the lung. J. Clin. Invest. 122(8), 2724-2730 (2012).
136. Endter S, Francombe D, Ehrhardt C, Gumbleton M. RT-PCR analysis of ABC, SLC and SLCO drug transporters in human lung epithelial cell models. J. Pharm. Pharmacol. 61(5), 583-591 (2009).
137. Stentebjerg-Andersen A, Notlevsen IV, Brodin B, Nielsen CU. Calu-3 cells grown under AIC and LCC conditions: implications for dipeptide uptake and transepithelial transport of substances. Eur. J. Pharm. Biopharm. 78(1), 19-26 (2011).
138. Frohlich E, Bonstingl G, Hofler A et al. Comparison of two in vitro systems to assess cellular effects of nanoparticles-containing aerosols. Toxicol. In Vitro 27(1), 409-417 (2013).
139. Geys J, Coenegrachts L, Vercammen J et al. In vitro study of the pulmonary translocation of nanoparticles: a preliminary study. Toxicol. Lett. 160(3), 218-226 (2006).
140. Drug development and drug interactions: table of substrates, inhibitors and inducers. www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ DrugInteractionsLabeling/ucm093664. htm#PgpTransport